Abstract 1866P
Background
The aim of this study was to compare sexual health between young breast cancer survivors and healthy young women without history of cancer, to better analyse the impact of breast cancer diagnosis and treatment on sexual health.
Methods
We conducted a cross-sectional study including all young breast cancer patients (≤40 year-old) referred for radiotherapy between 2017 and 2021. Patients were asked to fill in the Female Sexual Function Index (FSFI) in its validated Arabic translated version. A comparable cohort of young healthy women was recruited to fill in the same questionnaire. Sexual scores were calculated for both groups and statistically compared.
Results
A total of 102 young breast cancer patients (BC group) and 53 young healthy women (control group) were included in this study. Only 39.2% of breast cancer patients answered the questionnaire. Ninety-seven percent of patients underwent chemotherapy. Adjuvant endocrine therapy was prescribed for 77% of patients, of whom 97% underwent ovarian function suppression. All patients received adjuvant hypofractionated radiotherapy. Mean FSFI score was 24.01 (2.4-33) in the BC group versus 28.88 (23.8-34.4) in the control group (p=0.000). Two patients declared having unpleasurable sexual activities before their diagnosis. Sexual dysfunction (FSFI score < 26,55) was reported in 55% and 20%, respectively in the BC and control group (p=0.001). Mean desire score was 3.58 vs 4.08 (p=0.016), respectively in the BC group and the control group. Ninety-two percent of breast cancer patients suffered from hypoactive sexual desire disorder (desire score <5), versus 87% in the control group (p=0.35).
Table: 1866P
Female Sexual Function Index questionnaire scores
Domain | Breast cancer group | Control group | P value |
Desire | 3.58 | 4.08 | 0.016 |
Arousal | 3.71 | 4.56 | 0.001 |
Lubrification | 4.15 | 5.16 | 0.00 |
Orgasm | 4.23 | 4.97 | 0.007 |
Satisfaction | 4.44 | 5.49 | 0.00 |
Pain | 3.85 | 4.62 | 0.008 |
Conclusions
This study showed a significant alteration of sexual function in young breast cancer survivors when compared with a control group. Assessment and management of sexual dysfunction should become a standard practice, in order to improve quality of life and sexual health in young breast cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05